- Home
- Products
- Customized ADCs
- CD22
- Anti-CD22 (clone 10F4v3)-SPP-DM1 ADC
Anti-CD22 (clone 10F4v3)-SPP-DM1 ADC (CAT#: ADC-W-187)
This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v3) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- 10F4v3
- Name
- CD22
- Alternative Names
- CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;
- Target Entrez Gene ID
- 933
- Target UniProt ID
- P20273
- Overview
- CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.
CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
- Overview
- Humanized Anti-CD22 antibody, clone # 10F4v3
- Clone #
- 10F4v3
- Species Reactivity
- Human
- Name
- SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-FGFR2 (clone 10923)-sulfo-SMCC-DM1 ADC (CAT#: ADC-W-056)
- Anti-NRP1 (Vesencumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1681)
- Anti-MS4A1-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2618)
- Anti-PDCD1-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1697)
- Anti-TNF (Nerelimomab)-MC-MMAF ADC (CAT#: ADC-W-1858)
- Anti-LOXL2 (Simtuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1527)
- Anti-RTN4 (Atinumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1739)
- Anti-MET (Onartuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1541)
- Anti-Rabies Virus Glycoprotein (Foravirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1969)
- Anti-MSLN (Amatuximab)-SPDB-DM4 ADC (CAT#: ADC-W-1593)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-187. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2526 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2529 | Anti-CD22-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2533 | Anti-CD22 (Pinatuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2534 | Anti-CD22 (Pinatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2530 | Anti-CD22-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
CAT# | Product Name | Linker | Payload |
ADC-W-613 | Anti-CD19 (B496)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-625 | Anti-CD22 (10F4v3)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-321 | Anti-SDC1(nBT062)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-572 | Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-226 | Anti-ITIH4-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-AA-015 | anti-HIgG(Fc)Fab-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-487 | Anti-CD70-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-541 | Anti-CD44 (clone BIWA 4)-DM1 ADC | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | |
ADC-AA-031 | anti-MIgG(Fc)Fab-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-AA-050 | Protein G-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.